nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—MAPK3—kidney cancer	0.387	0.631	CbGaD
Sulindac—PTGS1—kidney cancer	0.0911	0.148	CbGaD
Sulindac—CYP1A1—kidney cancer	0.0833	0.136	CbGaD
Sulindac—PTGS2—kidney cancer	0.0521	0.0848	CbGaD
Sulindac—CYP1A1—Erlotinib—kidney cancer	0.0224	0.314	CbGbCtD
Sulindac—ALB—Erlotinib—kidney cancer	0.0168	0.235	CbGbCtD
Sulindac—CYP1A2—Pazopanib—kidney cancer	0.0141	0.197	CbGbCtD
Sulindac—CYP1A2—Erlotinib—kidney cancer	0.01	0.14	CbGbCtD
Sulindac—MAPK3—nephron—kidney cancer	0.00863	0.199	CbGeAlD
Sulindac—CYP1A2—Sorafenib—kidney cancer	0.00815	0.114	CbGbCtD
Sulindac—AKR1B1—nephron tubule—kidney cancer	0.00257	0.0594	CbGeAlD
Sulindac—AKR1B1—renal system—kidney cancer	0.00234	0.054	CbGeAlD
Sulindac—AKR1B1—kidney—kidney cancer	0.00226	0.0522	CbGeAlD
Sulindac—PTGS2—nephron—kidney cancer	0.00224	0.0518	CbGeAlD
Sulindac—AKR1B1—cortex of kidney—kidney cancer	0.0022	0.0508	CbGeAlD
Sulindac—CYP1A2—urine—kidney cancer	0.00217	0.0502	CbGeAlD
Sulindac—AKR1B1—gonad—kidney cancer	0.00209	0.0484	CbGeAlD
Sulindac—AKR1B1—cardiac atrium—kidney cancer	0.00209	0.0484	CbGeAlD
Sulindac—MAPK3—nephron tubule—kidney cancer	0.00186	0.0431	CbGeAlD
Sulindac—MAPK3—renal system—kidney cancer	0.00169	0.0391	CbGeAlD
Sulindac—MAPK3—kidney—kidney cancer	0.00164	0.0378	CbGeAlD
Sulindac—MAPK3—cortex of kidney—kidney cancer	0.00159	0.0368	CbGeAlD
Sulindac—MAPK3—gonad—kidney cancer	0.00152	0.0351	CbGeAlD
Sulindac—MAPK3—cardiac atrium—kidney cancer	0.00152	0.035	CbGeAlD
Sulindac—SLC22A6—nephron tubule—kidney cancer	0.00142	0.0329	CbGeAlD
Sulindac—SLC22A6—cortex of kidney—kidney cancer	0.00122	0.0282	CbGeAlD
Sulindac—CYP1A2—renal system—kidney cancer	0.000531	0.0123	CbGeAlD
Sulindac—CYP1A1—renal system—kidney cancer	0.000524	0.0121	CbGeAlD
Sulindac—CYP1A1—kidney—kidney cancer	0.000506	0.0117	CbGeAlD
Sulindac—CYP1A1—cardiac atrium—kidney cancer	0.000469	0.0108	CbGeAlD
Sulindac—PTGS1—renal system—kidney cancer	0.00046	0.0106	CbGeAlD
Sulindac—PTGS1—kidney—kidney cancer	0.000445	0.0103	CbGeAlD
Sulindac—PTGS2—renal system—kidney cancer	0.00044	0.0102	CbGeAlD
Sulindac—PTGS2—kidney—kidney cancer	0.000425	0.00983	CbGeAlD
Sulindac—PTGS1—cardiac atrium—kidney cancer	0.000412	0.00952	CbGeAlD
Sulindac—Anaemia—Paclitaxel—kidney cancer	9.11e-05	0.000615	CcSEcCtD
Sulindac—Renal impairment—Doxorubicin—kidney cancer	9.1e-05	0.000614	CcSEcCtD
Sulindac—Paraesthesia—Vincristine—kidney cancer	9.1e-05	0.000614	CcSEcCtD
Sulindac—Rash—Everolimus—kidney cancer	9.04e-05	0.00061	CcSEcCtD
Sulindac—Dermatitis—Everolimus—kidney cancer	9.03e-05	0.000609	CcSEcCtD
Sulindac—Headache—Vinblastine—kidney cancer	9.02e-05	0.000608	CcSEcCtD
Sulindac—Angioedema—Paclitaxel—kidney cancer	9.01e-05	0.000608	CcSEcCtD
Sulindac—Purpura—Doxorubicin—kidney cancer	8.98e-05	0.000606	CcSEcCtD
Sulindac—Headache—Everolimus—kidney cancer	8.98e-05	0.000606	CcSEcCtD
Sulindac—Hypotension—Gemcitabine—kidney cancer	8.98e-05	0.000606	CcSEcCtD
Sulindac—Body temperature increased—Dactinomycin—kidney cancer	8.96e-05	0.000605	CcSEcCtD
Sulindac—Visual impairment—Capecitabine—kidney cancer	8.96e-05	0.000604	CcSEcCtD
Sulindac—Asthenia—Sorafenib—kidney cancer	8.93e-05	0.000602	CcSEcCtD
Sulindac—Malaise—Paclitaxel—kidney cancer	8.89e-05	0.0006	CcSEcCtD
Sulindac—Vertigo—Paclitaxel—kidney cancer	8.86e-05	0.000597	CcSEcCtD
Sulindac—Syncope—Paclitaxel—kidney cancer	8.84e-05	0.000596	CcSEcCtD
Sulindac—Leukopenia—Paclitaxel—kidney cancer	8.82e-05	0.000595	CcSEcCtD
Sulindac—Hypersensitivity—Sunitinib—kidney cancer	8.82e-05	0.000595	CcSEcCtD
Sulindac—Decreased appetite—Vincristine—kidney cancer	8.81e-05	0.000594	CcSEcCtD
Sulindac—Pruritus—Sorafenib—kidney cancer	8.81e-05	0.000594	CcSEcCtD
Sulindac—Vomiting—Erlotinib—kidney cancer	8.8e-05	0.000593	CcSEcCtD
Sulindac—Erythema multiforme—Capecitabine—kidney cancer	8.79e-05	0.000593	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Gemcitabine—kidney cancer	8.76e-05	0.000591	CcSEcCtD
Sulindac—Fatigue—Vincristine—kidney cancer	8.73e-05	0.000589	CcSEcCtD
Sulindac—Rash—Erlotinib—kidney cancer	8.72e-05	0.000588	CcSEcCtD
Sulindac—Dermatitis—Erlotinib—kidney cancer	8.72e-05	0.000588	CcSEcCtD
Sulindac—Palpitations—Paclitaxel—kidney cancer	8.71e-05	0.000588	CcSEcCtD
Sulindac—Insomnia—Gemcitabine—kidney cancer	8.69e-05	0.000586	CcSEcCtD
Sulindac—Headache—Erlotinib—kidney cancer	8.67e-05	0.000585	CcSEcCtD
Sulindac—Tinnitus—Capecitabine—kidney cancer	8.67e-05	0.000584	CcSEcCtD
Sulindac—Loss of consciousness—Paclitaxel—kidney cancer	8.66e-05	0.000584	CcSEcCtD
Sulindac—Constipation—Vincristine—kidney cancer	8.66e-05	0.000584	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	8.66e-05	0.000584	CcSEcCtD
Sulindac—Paraesthesia—Gemcitabine—kidney cancer	8.63e-05	0.000582	CcSEcCtD
Sulindac—Flushing—Capecitabine—kidney cancer	8.63e-05	0.000582	CcSEcCtD
Sulindac—Asthenia—Sunitinib—kidney cancer	8.59e-05	0.00058	CcSEcCtD
Sulindac—Dyspnoea—Gemcitabine—kidney cancer	8.57e-05	0.000578	CcSEcCtD
Sulindac—Nausea—Vinblastine—kidney cancer	8.55e-05	0.000577	CcSEcCtD
Sulindac—Somnolence—Gemcitabine—kidney cancer	8.54e-05	0.000576	CcSEcCtD
Sulindac—Convulsion—Paclitaxel—kidney cancer	8.54e-05	0.000576	CcSEcCtD
Sulindac—Nausea—Everolimus—kidney cancer	8.52e-05	0.000574	CcSEcCtD
Sulindac—Diarrhoea—Sorafenib—kidney cancer	8.52e-05	0.000574	CcSEcCtD
Sulindac—Hypertension—Paclitaxel—kidney cancer	8.51e-05	0.000574	CcSEcCtD
Sulindac—Pruritus—Sunitinib—kidney cancer	8.47e-05	0.000571	CcSEcCtD
Sulindac—Myalgia—Paclitaxel—kidney cancer	8.39e-05	0.000566	CcSEcCtD
Sulindac—Chest pain—Paclitaxel—kidney cancer	8.39e-05	0.000566	CcSEcCtD
Sulindac—Arthralgia—Paclitaxel—kidney cancer	8.39e-05	0.000566	CcSEcCtD
Sulindac—Decreased appetite—Gemcitabine—kidney cancer	8.35e-05	0.000563	CcSEcCtD
Sulindac—Hypersensitivity—Dactinomycin—kidney cancer	8.35e-05	0.000563	CcSEcCtD
Sulindac—Chills—Capecitabine—kidney cancer	8.34e-05	0.000562	CcSEcCtD
Sulindac—Arrhythmia—Capecitabine—kidney cancer	8.3e-05	0.00056	CcSEcCtD
Sulindac—Discomfort—Paclitaxel—kidney cancer	8.29e-05	0.000559	CcSEcCtD
Sulindac—Fatigue—Gemcitabine—kidney cancer	8.29e-05	0.000559	CcSEcCtD
Sulindac—Gastrointestinal pain—Vincristine—kidney cancer	8.28e-05	0.000559	CcSEcCtD
Sulindac—Dizziness—Sorafenib—kidney cancer	8.23e-05	0.000555	CcSEcCtD
Sulindac—Constipation—Gemcitabine—kidney cancer	8.22e-05	0.000554	CcSEcCtD
Sulindac—Nausea—Erlotinib—kidney cancer	8.22e-05	0.000554	CcSEcCtD
Sulindac—Alopecia—Capecitabine—kidney cancer	8.21e-05	0.000554	CcSEcCtD
Sulindac—Diarrhoea—Sunitinib—kidney cancer	8.19e-05	0.000553	CcSEcCtD
Sulindac—Asthenia—Dactinomycin—kidney cancer	8.13e-05	0.000549	CcSEcCtD
Sulindac—Anaphylactic shock—Paclitaxel—kidney cancer	8.05e-05	0.000543	CcSEcCtD
Sulindac—Oedema—Paclitaxel—kidney cancer	8.05e-05	0.000543	CcSEcCtD
Sulindac—Body temperature increased—Vincristine—kidney cancer	8.01e-05	0.00054	CcSEcCtD
Sulindac—Flatulence—Capecitabine—kidney cancer	7.97e-05	0.000538	CcSEcCtD
Sulindac—Dysgeusia—Capecitabine—kidney cancer	7.92e-05	0.000534	CcSEcCtD
Sulindac—Dizziness—Sunitinib—kidney cancer	7.92e-05	0.000534	CcSEcCtD
Sulindac—Feeling abnormal—Gemcitabine—kidney cancer	7.92e-05	0.000534	CcSEcCtD
Sulindac—Shock—Paclitaxel—kidney cancer	7.92e-05	0.000534	CcSEcCtD
Sulindac—Vomiting—Sorafenib—kidney cancer	7.91e-05	0.000534	CcSEcCtD
Sulindac—Thrombocytopenia—Paclitaxel—kidney cancer	7.88e-05	0.000531	CcSEcCtD
Sulindac—Tachycardia—Paclitaxel—kidney cancer	7.85e-05	0.00053	CcSEcCtD
Sulindac—Rash—Sorafenib—kidney cancer	7.85e-05	0.000529	CcSEcCtD
Sulindac—Dermatitis—Sorafenib—kidney cancer	7.84e-05	0.000529	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	7.8e-05	0.000526	CcSEcCtD
Sulindac—Headache—Sorafenib—kidney cancer	7.8e-05	0.000526	CcSEcCtD
Sulindac—Hyperhidrosis—Paclitaxel—kidney cancer	7.78e-05	0.000525	CcSEcCtD
Sulindac—Diarrhoea—Dactinomycin—kidney cancer	7.76e-05	0.000523	CcSEcCtD
Sulindac—Anorexia—Paclitaxel—kidney cancer	7.67e-05	0.000517	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—kidney cancer	7.66e-05	0.000517	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—kidney cancer	7.64e-05	0.000515	CcSEcCtD
Sulindac—Vision blurred—Capecitabine—kidney cancer	7.62e-05	0.000514	CcSEcCtD
Sulindac—Vomiting—Sunitinib—kidney cancer	7.62e-05	0.000514	CcSEcCtD
Sulindac—Body temperature increased—Gemcitabine—kidney cancer	7.6e-05	0.000512	CcSEcCtD
Sulindac—Rash—Sunitinib—kidney cancer	7.55e-05	0.000509	CcSEcCtD
Sulindac—Dermatitis—Sunitinib—kidney cancer	7.54e-05	0.000509	CcSEcCtD
Sulindac—Hypotension—Paclitaxel—kidney cancer	7.52e-05	0.000507	CcSEcCtD
Sulindac—Ill-defined disorder—Capecitabine—kidney cancer	7.51e-05	0.000506	CcSEcCtD
Sulindac—Headache—Sunitinib—kidney cancer	7.5e-05	0.000506	CcSEcCtD
Sulindac—Anaemia—Capecitabine—kidney cancer	7.48e-05	0.000504	CcSEcCtD
Sulindac—Hypersensitivity—Vincristine—kidney cancer	7.46e-05	0.000503	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—kidney cancer	7.41e-05	0.0005	CcSEcCtD
Sulindac—Nausea—Sorafenib—kidney cancer	7.39e-05	0.000499	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—kidney cancer	7.34e-05	0.000495	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.33e-05	0.000494	CcSEcCtD
Sulindac—Malaise—Capecitabine—kidney cancer	7.3e-05	0.000492	CcSEcCtD
Sulindac—Insomnia—Paclitaxel—kidney cancer	7.28e-05	0.000491	CcSEcCtD
Sulindac—Vertigo—Capecitabine—kidney cancer	7.27e-05	0.00049	CcSEcCtD
Sulindac—Asthenia—Vincristine—kidney cancer	7.27e-05	0.00049	CcSEcCtD
Sulindac—Syncope—Capecitabine—kidney cancer	7.26e-05	0.000489	CcSEcCtD
Sulindac—Leukopenia—Capecitabine—kidney cancer	7.24e-05	0.000488	CcSEcCtD
Sulindac—Paraesthesia—Paclitaxel—kidney cancer	7.22e-05	0.000487	CcSEcCtD
Sulindac—Vomiting—Dactinomycin—kidney cancer	7.21e-05	0.000486	CcSEcCtD
Sulindac—Dyspnoea—Paclitaxel—kidney cancer	7.17e-05	0.000484	CcSEcCtD
Sulindac—Somnolence—Paclitaxel—kidney cancer	7.15e-05	0.000482	CcSEcCtD
Sulindac—Palpitations—Capecitabine—kidney cancer	7.15e-05	0.000482	CcSEcCtD
Sulindac—Rash—Dactinomycin—kidney cancer	7.15e-05	0.000482	CcSEcCtD
Sulindac—Nausea—Sunitinib—kidney cancer	7.11e-05	0.00048	CcSEcCtD
Sulindac—Loss of consciousness—Capecitabine—kidney cancer	7.11e-05	0.00048	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—kidney cancer	7.11e-05	0.000479	CcSEcCtD
Sulindac—Dyspepsia—Paclitaxel—kidney cancer	7.08e-05	0.000478	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—kidney cancer	7e-05	0.000472	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—kidney cancer	7e-05	0.000472	CcSEcCtD
Sulindac—Decreased appetite—Paclitaxel—kidney cancer	6.99e-05	0.000472	CcSEcCtD
Sulindac—Hypertension—Capecitabine—kidney cancer	6.98e-05	0.000471	CcSEcCtD
Sulindac—Fatigue—Paclitaxel—kidney cancer	6.94e-05	0.000468	CcSEcCtD
Sulindac—Diarrhoea—Vincristine—kidney cancer	6.93e-05	0.000467	CcSEcCtD
Sulindac—Asthenia—Gemcitabine—kidney cancer	6.9e-05	0.000465	CcSEcCtD
Sulindac—Arthralgia—Capecitabine—kidney cancer	6.89e-05	0.000465	CcSEcCtD
Sulindac—Chest pain—Capecitabine—kidney cancer	6.89e-05	0.000465	CcSEcCtD
Sulindac—Myalgia—Capecitabine—kidney cancer	6.89e-05	0.000465	CcSEcCtD
Sulindac—Constipation—Paclitaxel—kidney cancer	6.88e-05	0.000464	CcSEcCtD
Sulindac—Photosensitivity reaction—Doxorubicin—kidney cancer	6.83e-05	0.000461	CcSEcCtD
Sulindac—Discomfort—Capecitabine—kidney cancer	6.81e-05	0.000459	CcSEcCtD
Sulindac—Pruritus—Gemcitabine—kidney cancer	6.8e-05	0.000459	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—kidney cancer	6.75e-05	0.000455	CcSEcCtD
Sulindac—Nausea—Dactinomycin—kidney cancer	6.73e-05	0.000454	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—kidney cancer	6.71e-05	0.000453	CcSEcCtD
Sulindac—Dizziness—Vincristine—kidney cancer	6.7e-05	0.000452	CcSEcCtD
Sulindac—Feeling abnormal—Paclitaxel—kidney cancer	6.63e-05	0.000447	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	6.62e-05	0.000446	CcSEcCtD
Sulindac—Oedema—Capecitabine—kidney cancer	6.6e-05	0.000445	CcSEcCtD
Sulindac—Gastrointestinal pain—Paclitaxel—kidney cancer	6.58e-05	0.000444	CcSEcCtD
Sulindac—Diarrhoea—Gemcitabine—kidney cancer	6.58e-05	0.000443	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—kidney cancer	6.56e-05	0.000442	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—kidney cancer	6.54e-05	0.000441	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—kidney cancer	6.5e-05	0.000439	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—kidney cancer	6.5e-05	0.000439	CcSEcCtD
Sulindac—Shock—Capecitabine—kidney cancer	6.5e-05	0.000438	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—kidney cancer	6.49e-05	0.000437	CcSEcCtD
Sulindac—Thrombocytopenia—Capecitabine—kidney cancer	6.46e-05	0.000436	CcSEcCtD
Sulindac—Tachycardia—Capecitabine—kidney cancer	6.44e-05	0.000435	CcSEcCtD
Sulindac—Vomiting—Vincristine—kidney cancer	6.44e-05	0.000434	CcSEcCtD
Sulindac—Sweating—Doxorubicin—kidney cancer	6.4e-05	0.000431	CcSEcCtD
Sulindac—Urticaria—Paclitaxel—kidney cancer	6.39e-05	0.000431	CcSEcCtD
Sulindac—Rash—Vincristine—kidney cancer	6.39e-05	0.000431	CcSEcCtD
Sulindac—Hyperhidrosis—Capecitabine—kidney cancer	6.38e-05	0.000431	CcSEcCtD
Sulindac—Dermatitis—Vincristine—kidney cancer	6.38e-05	0.00043	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—kidney cancer	6.36e-05	0.000429	CcSEcCtD
Sulindac—Body temperature increased—Paclitaxel—kidney cancer	6.36e-05	0.000429	CcSEcCtD
Sulindac—Headache—Vincristine—kidney cancer	6.35e-05	0.000428	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—kidney cancer	6.29e-05	0.000425	CcSEcCtD
Sulindac—Anorexia—Capecitabine—kidney cancer	6.29e-05	0.000424	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—kidney cancer	6.23e-05	0.00042	CcSEcCtD
Sulindac—Hypotension—Capecitabine—kidney cancer	6.17e-05	0.000416	CcSEcCtD
Sulindac—Vomiting—Gemcitabine—kidney cancer	6.11e-05	0.000412	CcSEcCtD
Sulindac—Rash—Gemcitabine—kidney cancer	6.06e-05	0.000409	CcSEcCtD
Sulindac—Dermatitis—Gemcitabine—kidney cancer	6.05e-05	0.000408	CcSEcCtD
Sulindac—Headache—Gemcitabine—kidney cancer	6.02e-05	0.000406	CcSEcCtD
Sulindac—Nausea—Vincristine—kidney cancer	6.02e-05	0.000406	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Capecitabine—kidney cancer	6.02e-05	0.000406	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—kidney cancer	5.99e-05	0.000404	CcSEcCtD
Sulindac—Insomnia—Capecitabine—kidney cancer	5.97e-05	0.000403	CcSEcCtD
Sulindac—Paraesthesia—Capecitabine—kidney cancer	5.93e-05	0.0004	CcSEcCtD
Sulindac—Hypersensitivity—Paclitaxel—kidney cancer	5.93e-05	0.0004	CcSEcCtD
Sulindac—Dyspnoea—Capecitabine—kidney cancer	5.89e-05	0.000397	CcSEcCtD
Sulindac—Dyspepsia—Capecitabine—kidney cancer	5.81e-05	0.000392	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—kidney cancer	5.77e-05	0.000389	CcSEcCtD
Sulindac—Asthenia—Paclitaxel—kidney cancer	5.77e-05	0.000389	CcSEcCtD
Sulindac—Decreased appetite—Capecitabine—kidney cancer	5.74e-05	0.000387	CcSEcCtD
Sulindac—Nausea—Gemcitabine—kidney cancer	5.71e-05	0.000385	CcSEcCtD
Sulindac—Fatigue—Capecitabine—kidney cancer	5.69e-05	0.000384	CcSEcCtD
Sulindac—Pruritus—Paclitaxel—kidney cancer	5.69e-05	0.000384	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—kidney cancer	5.66e-05	0.000382	CcSEcCtD
Sulindac—Constipation—Capecitabine—kidney cancer	5.65e-05	0.000381	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—kidney cancer	5.59e-05	0.000377	CcSEcCtD
Sulindac—Flushing—Doxorubicin—kidney cancer	5.56e-05	0.000375	CcSEcCtD
Sulindac—Diarrhoea—Paclitaxel—kidney cancer	5.51e-05	0.000371	CcSEcCtD
Sulindac—Feeling abnormal—Capecitabine—kidney cancer	5.44e-05	0.000367	CcSEcCtD
Sulindac—Gastrointestinal pain—Capecitabine—kidney cancer	5.4e-05	0.000364	CcSEcCtD
Sulindac—Chills—Doxorubicin—kidney cancer	5.38e-05	0.000363	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—kidney cancer	5.35e-05	0.000361	CcSEcCtD
Sulindac—Dizziness—Paclitaxel—kidney cancer	5.32e-05	0.000359	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—kidney cancer	5.29e-05	0.000357	CcSEcCtD
Sulindac—Urticaria—Capecitabine—kidney cancer	5.25e-05	0.000354	CcSEcCtD
Sulindac—Body temperature increased—Capecitabine—kidney cancer	5.22e-05	0.000352	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—kidney cancer	5.14e-05	0.000347	CcSEcCtD
Sulindac—Tension—Doxorubicin—kidney cancer	5.12e-05	0.000345	CcSEcCtD
Sulindac—Vomiting—Paclitaxel—kidney cancer	5.12e-05	0.000345	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—kidney cancer	5.11e-05	0.000344	CcSEcCtD
Sulindac—Rash—Paclitaxel—kidney cancer	5.07e-05	0.000342	CcSEcCtD
Sulindac—Dermatitis—Paclitaxel—kidney cancer	5.07e-05	0.000342	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—kidney cancer	5.07e-05	0.000342	CcSEcCtD
Sulindac—Headache—Paclitaxel—kidney cancer	5.04e-05	0.00034	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—kidney cancer	4.91e-05	0.000331	CcSEcCtD
Sulindac—Hypersensitivity—Capecitabine—kidney cancer	4.86e-05	0.000328	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—kidney cancer	4.84e-05	0.000326	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—kidney cancer	4.82e-05	0.000325	CcSEcCtD
Sulindac—Nausea—Paclitaxel—kidney cancer	4.78e-05	0.000322	CcSEcCtD
Sulindac—Asthenia—Capecitabine—kidney cancer	4.74e-05	0.00032	CcSEcCtD
Sulindac—Malaise—Doxorubicin—kidney cancer	4.7e-05	0.000317	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—kidney cancer	4.69e-05	0.000316	CcSEcCtD
Sulindac—Syncope—Doxorubicin—kidney cancer	4.68e-05	0.000315	CcSEcCtD
Sulindac—Pruritus—Capecitabine—kidney cancer	4.67e-05	0.000315	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—kidney cancer	4.67e-05	0.000315	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—kidney cancer	4.61e-05	0.000311	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—kidney cancer	4.58e-05	0.000309	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—kidney cancer	4.52e-05	0.000305	CcSEcCtD
Sulindac—Diarrhoea—Capecitabine—kidney cancer	4.52e-05	0.000305	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—kidney cancer	4.5e-05	0.000304	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—kidney cancer	4.44e-05	0.000299	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—kidney cancer	4.44e-05	0.000299	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—kidney cancer	4.44e-05	0.000299	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—kidney cancer	4.39e-05	0.000296	CcSEcCtD
Sulindac—Dizziness—Capecitabine—kidney cancer	4.37e-05	0.000294	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—kidney cancer	4.26e-05	0.000287	CcSEcCtD
Sulindac—Oedema—Doxorubicin—kidney cancer	4.26e-05	0.000287	CcSEcCtD
Sulindac—Vomiting—Capecitabine—kidney cancer	4.2e-05	0.000283	CcSEcCtD
Sulindac—Shock—Doxorubicin—kidney cancer	4.19e-05	0.000282	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—kidney cancer	4.17e-05	0.000281	CcSEcCtD
Sulindac—Rash—Capecitabine—kidney cancer	4.16e-05	0.000281	CcSEcCtD
Sulindac—Dermatitis—Capecitabine—kidney cancer	4.16e-05	0.000281	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—kidney cancer	4.15e-05	0.00028	CcSEcCtD
Sulindac—Headache—Capecitabine—kidney cancer	4.14e-05	0.000279	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—kidney cancer	4.11e-05	0.000278	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—kidney cancer	4.06e-05	0.000274	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—kidney cancer	3.98e-05	0.000268	CcSEcCtD
Sulindac—Nausea—Capecitabine—kidney cancer	3.92e-05	0.000265	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.88e-05	0.000262	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—kidney cancer	3.85e-05	0.00026	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—kidney cancer	3.82e-05	0.000258	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—kidney cancer	3.79e-05	0.000256	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—kidney cancer	3.78e-05	0.000255	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—kidney cancer	3.75e-05	0.000253	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—kidney cancer	3.7e-05	0.00025	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—kidney cancer	3.67e-05	0.000247	CcSEcCtD
Sulindac—Constipation—Doxorubicin—kidney cancer	3.64e-05	0.000245	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—kidney cancer	3.51e-05	0.000237	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—kidney cancer	3.48e-05	0.000235	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—kidney cancer	3.38e-05	0.000228	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—kidney cancer	3.36e-05	0.000227	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—kidney cancer	3.14e-05	0.000211	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—kidney cancer	3.05e-05	0.000206	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—kidney cancer	3.01e-05	0.000203	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—kidney cancer	2.91e-05	0.000196	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—kidney cancer	2.81e-05	0.00019	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—kidney cancer	2.71e-05	0.000183	CcSEcCtD
Sulindac—Rash—Doxorubicin—kidney cancer	2.68e-05	0.000181	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—kidney cancer	2.68e-05	0.000181	CcSEcCtD
Sulindac—Headache—Doxorubicin—kidney cancer	2.67e-05	0.00018	CcSEcCtD
Sulindac—Nausea—Doxorubicin—kidney cancer	2.53e-05	0.000171	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—JUN—kidney cancer	8.41e-06	6.84e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	8.37e-06	6.8e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CTNNB1—kidney cancer	8.35e-06	6.79e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—kidney cancer	8.32e-06	6.76e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SCARB1—kidney cancer	8.3e-06	6.74e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	8.29e-06	6.74e-05	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	8.27e-06	6.72e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—kidney cancer	8.23e-06	6.69e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CRABP1—kidney cancer	8.21e-06	6.67e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KRAS—kidney cancer	8.2e-06	6.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—kidney cancer	8.17e-06	6.64e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PTEN—kidney cancer	8.14e-06	6.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—TSC2—kidney cancer	8.11e-06	6.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUNB—kidney cancer	8.07e-06	6.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PAK1—kidney cancer	8.07e-06	6.56e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PSMD7—kidney cancer	8.06e-06	6.55e-05	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	8e-06	6.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—MYC—kidney cancer	7.93e-06	6.44e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—ABCB1—kidney cancer	7.89e-06	6.41e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—MAPK3—kidney cancer	7.89e-06	6.41e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APRT—kidney cancer	7.88e-06	6.41e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—FH—kidney cancer	7.88e-06	6.41e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CA9—kidney cancer	7.81e-06	6.35e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—MAPK1—kidney cancer	7.76e-06	6.3e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	7.71e-06	6.26e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—MYC—kidney cancer	7.67e-06	6.23e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—BCHE—kidney cancer	7.64e-06	6.21e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PSMD7—kidney cancer	7.64e-06	6.21e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	7.64e-06	6.2e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ITPR2—kidney cancer	7.63e-06	6.2e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	7.62e-06	6.19e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SLC5A5—kidney cancer	7.55e-06	6.13e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PIK3CA—kidney cancer	7.53e-06	6.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HIF1A—kidney cancer	7.5e-06	6.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MAPK1—kidney cancer	7.49e-06	6.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TSC2—kidney cancer	7.48e-06	6.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—POMC—kidney cancer	7.46e-06	6.06e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GPC3—kidney cancer	7.41e-06	6.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—MAPK1—kidney cancer	7.35e-06	5.97e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—kidney cancer	7.29e-06	5.92e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CRABP1—kidney cancer	7.29e-06	5.92e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SLC2A1—kidney cancer	7.29e-06	5.92e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CA2—kidney cancer	7.21e-06	5.86e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	7.21e-06	5.86e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTEN—kidney cancer	7.18e-06	5.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KIT—kidney cancer	7.16e-06	5.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MYC—kidney cancer	7.09e-06	5.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—KRAS—kidney cancer	7.08e-06	5.75e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	7.07e-06	5.75e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	7.04e-06	5.72e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALAD—kidney cancer	7.03e-06	5.71e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTT1—kidney cancer	6.96e-06	5.66e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ACHE—kidney cancer	6.96e-06	5.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—KRAS—kidney cancer	6.94e-06	5.64e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MAPK1—kidney cancer	6.94e-06	5.64e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SLC2A1—kidney cancer	6.91e-06	5.61e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	6.86e-06	5.58e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ST3GAL2—kidney cancer	6.86e-06	5.57e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—JUNB—kidney cancer	6.86e-06	5.57e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ITPR2—kidney cancer	6.77e-06	5.51e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALDH1A1—kidney cancer	6.7e-06	5.45e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CRABP1—kidney cancer	6.64e-06	5.4e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—MAPK1—kidney cancer	6.62e-06	5.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KIT—kidney cancer	6.61e-06	5.37e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—APC—kidney cancer	6.61e-06	5.37e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF2—kidney cancer	6.6e-06	5.36e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDH1—kidney cancer	6.59e-06	5.35e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SCARB1—kidney cancer	6.59e-06	5.35e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN2B—kidney cancer	6.57e-06	5.34e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTGS1—kidney cancer	6.52e-06	5.3e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PGK1—kidney cancer	6.43e-06	5.22e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC5A3—kidney cancer	6.43e-06	5.22e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PSMD7—kidney cancer	6.4e-06	5.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1R—kidney cancer	6.38e-06	5.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—PIK3CA—kidney cancer	6.38e-06	5.18e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—LDHB—kidney cancer	6.3e-06	5.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—kidney cancer	6.25e-06	5.08e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.25e-06	5.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—BRAF—kidney cancer	6.21e-06	5.05e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTT1—kidney cancer	6.18e-06	5.02e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ACHE—kidney cancer	6.18e-06	5.02e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ITPR2—kidney cancer	6.18e-06	5.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—kidney cancer	6.17e-06	5.01e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.17e-06	5.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—RAF1—kidney cancer	6.15e-06	5e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSTP1—kidney cancer	6.08e-06	4.94e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—BCHE—kidney cancer	6.06e-06	4.93e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC5A5—kidney cancer	5.99e-06	4.87e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	5.95e-06	4.84e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SCARB1—kidney cancer	5.85e-06	4.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—kidney cancer	5.82e-06	4.73e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS1—kidney cancer	5.79e-06	4.7e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC2A1—kidney cancer	5.78e-06	4.7e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ABCB1—kidney cancer	5.75e-06	4.68e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PIK3CA—kidney cancer	5.74e-06	4.67e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.69e-06	4.63e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PSMD7—kidney cancer	5.68e-06	4.61e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTT1—kidney cancer	5.63e-06	4.58e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ACHE—kidney cancer	5.63e-06	4.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—RAF1—kidney cancer	5.62e-06	4.57e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—RELA—kidney cancer	5.59e-06	4.55e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSTM1—kidney cancer	5.59e-06	4.54e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN2B—kidney cancer	5.58e-06	4.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ERBB2—kidney cancer	5.56e-06	4.52e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2—kidney cancer	5.51e-06	4.48e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MTOR—kidney cancer	5.49e-06	4.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD4—kidney cancer	5.48e-06	4.45e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CA9—kidney cancer	5.46e-06	4.44e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—BCHE—kidney cancer	5.38e-06	4.37e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	5.34e-06	4.34e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SCARB1—kidney cancer	5.33e-06	4.33e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC5A5—kidney cancer	5.32e-06	4.32e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP1A1—kidney cancer	5.29e-06	4.3e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS1—kidney cancer	5.28e-06	4.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HIF1A—kidney cancer	5.25e-06	4.27e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TSC2—kidney cancer	5.24e-06	4.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—RAF1—kidney cancer	5.19e-06	4.22e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PSMD7—kidney cancer	5.18e-06	4.21e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—RAF1—kidney cancer	5.16e-06	4.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDKN1B—kidney cancer	5.15e-06	4.18e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC2A1—kidney cancer	5.13e-06	4.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—ERBB2—kidney cancer	5.13e-06	4.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MTOR—kidney cancer	5.07e-06	4.12e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PIK3CA—kidney cancer	5.06e-06	4.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD4—kidney cancer	5.06e-06	4.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2—kidney cancer	5.04e-06	4.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KDR—kidney cancer	5.02e-06	4.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—kidney cancer	5.02e-06	4.08e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.98e-06	4.05e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—BCHE—kidney cancer	4.91e-06	3.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—JUN—kidney cancer	4.9e-06	3.98e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.89e-06	3.98e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CTNNB1—kidney cancer	4.86e-06	3.95e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC5A5—kidney cancer	4.85e-06	3.94e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTP1—kidney cancer	4.82e-06	3.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1B—kidney cancer	4.75e-06	3.86e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTEN—kidney cancer	4.74e-06	3.85e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC2A1—kidney cancer	4.68e-06	3.8e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CRABP1—kidney cancer	4.65e-06	3.78e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APC—kidney cancer	4.63e-06	3.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KIT—kidney cancer	4.63e-06	3.76e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—kidney cancer	4.62e-06	3.76e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ABCB1—kidney cancer	4.57e-06	3.71e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.54e-06	3.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CTNNB1—kidney cancer	4.49e-06	3.65e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	4.46e-06	3.63e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HIF1A—kidney cancer	4.46e-06	3.63e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TSC2—kidney cancer	4.45e-06	3.62e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTM1—kidney cancer	4.43e-06	3.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—POMC—kidney cancer	4.41e-06	3.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTEN—kidney cancer	4.38e-06	3.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BRAF—kidney cancer	4.35e-06	3.54e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.35e-06	3.53e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.34e-06	3.53e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ITPR2—kidney cancer	4.32e-06	3.51e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTP1—kidney cancer	4.28e-06	3.48e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—MAPK1—kidney cancer	4.22e-06	3.43e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP1A1—kidney cancer	4.2e-06	3.42e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ABCB1—kidney cancer	4.05e-06	3.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—kidney cancer	3.98e-06	3.24e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.98e-06	3.24e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.96e-06	3.22e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—POMC—kidney cancer	3.95e-06	3.21e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ACHE—kidney cancer	3.94e-06	3.2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTT1—kidney cancer	3.94e-06	3.2e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTM1—kidney cancer	3.93e-06	3.2e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KIT—kidney cancer	3.93e-06	3.19e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APC—kidney cancer	3.93e-06	3.19e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—kidney cancer	3.93e-06	3.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—kidney cancer	3.92e-06	3.18e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTP1—kidney cancer	3.9e-06	3.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MAPK1—kidney cancer	3.85e-06	3.13e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SCARB1—kidney cancer	3.73e-06	3.03e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK3—kidney cancer	3.72e-06	3.02e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BRAF—kidney cancer	3.7e-06	3e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ABCB1—kidney cancer	3.69e-06	3e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS1—kidney cancer	3.69e-06	3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—kidney cancer	3.66e-06	2.97e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—kidney cancer	3.64e-06	2.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—kidney cancer	3.64e-06	2.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RAF1—kidney cancer	3.63e-06	2.95e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PSMD7—kidney cancer	3.62e-06	2.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RELA—kidney cancer	3.62e-06	2.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ERBB2—kidney cancer	3.59e-06	2.92e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTM1—kidney cancer	3.59e-06	2.91e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MAPK1—kidney cancer	3.56e-06	2.89e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MTOR—kidney cancer	3.55e-06	2.88e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK1—kidney cancer	3.54e-06	2.87e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.45e-06	2.81e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—BCHE—kidney cancer	3.43e-06	2.79e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP1A1—kidney cancer	3.4e-06	2.76e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC5A5—kidney cancer	3.39e-06	2.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—kidney cancer	3.36e-06	2.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—kidney cancer	3.34e-06	2.72e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—kidney cancer	3.34e-06	2.71e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1B—kidney cancer	3.33e-06	2.7e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC2A1—kidney cancer	3.27e-06	2.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—kidney cancer	3.26e-06	2.65e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.18e-06	2.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—kidney cancer	3.18e-06	2.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUN—kidney cancer	3.17e-06	2.58e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—kidney cancer	3.15e-06	2.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CTNNB1—kidney cancer	3.14e-06	2.56e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—POMC—kidney cancer	3.13e-06	2.55e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—kidney cancer	3.09e-06	2.51e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—RAF1—kidney cancer	3.09e-06	2.51e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—kidney cancer	3.07e-06	2.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTEN—kidney cancer	3.06e-06	2.49e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.06e-06	2.49e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERBB2—kidney cancer	3.05e-06	2.48e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTOR—kidney cancer	3.01e-06	2.45e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD4—kidney cancer	3.01e-06	2.44e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—kidney cancer	2.97e-06	2.41e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1B—kidney cancer	2.83e-06	2.3e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.79e-06	2.27e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—POMC—kidney cancer	2.78e-06	2.26e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.77e-06	2.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—kidney cancer	2.77e-06	2.25e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTEN—kidney cancer	2.75e-06	2.23e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTP1—kidney cancer	2.73e-06	2.22e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CTNNB1—kidney cancer	2.67e-06	2.17e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTEN—kidney cancer	2.6e-06	2.12e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCB1—kidney cancer	2.58e-06	2.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—kidney cancer	2.55e-06	2.07e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—POMC—kidney cancer	2.54e-06	2.06e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTM1—kidney cancer	2.51e-06	2.04e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK1—kidney cancer	2.49e-06	2.02e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP1A1—kidney cancer	2.38e-06	1.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—kidney cancer	2.35e-06	1.91e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK3—kidney cancer	2.22e-06	1.81e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—kidney cancer	2.22e-06	1.8e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTEN—kidney cancer	2.18e-06	1.77e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—kidney cancer	2.16e-06	1.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—kidney cancer	2.16e-06	1.76e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK1—kidney cancer	2.12e-06	1.72e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—kidney cancer	2.09e-06	1.7e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—kidney cancer	2.02e-06	1.64e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—kidney cancer	2e-06	1.62e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.95e-06	1.59e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—kidney cancer	1.94e-06	1.57e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTEN—kidney cancer	1.93e-06	1.57e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—kidney cancer	1.84e-06	1.49e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—POMC—kidney cancer	1.77e-06	1.44e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTEN—kidney cancer	1.76e-06	1.43e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—kidney cancer	1.54e-06	1.25e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—kidney cancer	1.41e-06	1.15e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—kidney cancer	1.24e-06	1.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTEN—kidney cancer	1.23e-06	1e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—kidney cancer	8.7e-07	7.07e-06	CbGpPWpGaD
